1 / 1

INTRODUCTION

Decreased IL-6 and TNF-a secretion and increased GLP-1 and CD4+CD25+Fox p3+ T cells in response to oral administration of Hoodia parviflora alleviates insulin resistance and liver damage: Results of a Phase I clinical trial.

dawn-austin
Download Presentation

INTRODUCTION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Decreased IL-6 and TNF-a secretion and increased GLP-1 and CD4+CD25+Foxp3+ T cells in response to oral administration of Hoodia parviflora alleviates insulin resistance and liver damage: Results of a Phase I clinical trial Meir Mizrahi, Ami Ben Ya'acov, Tomer Adar,Gadi Lalazar, Yehudit Shabat, Refael Aharon,Yaron Ilan*. Liver Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Desert Labs Israel. Day 0 Day 30 INTRODUCTION • Metabolic syndrome is a chronic inflammatory disorder associated with insulin resistance and hepatic steatosis. • Extracts of the succulent Hoodia parviflora (HP) exert an immunomodulatory effect alleviating target organ damage in rodents. • Aim: To determine the safety and efficacy of oral administration of HP extracts to patients with insulin resistance and NAFLD. CD4+CD25+ cells (p<0.01) improved cholestatic liver enzymes levels p<0.04. p<0.002 TG levels (p<0.05) Day 30 Day 0 METHODS • Open-label trial. • HPwas daily orally administered to 10 patients for 30 days. • Subjects were monitored for safety, and serum levels of TNF-a, IL-6, adiponectin, GLP-1 and for the specific phenotypic markers of regulatory T cells in their PBMCs. • The clinical effect was evaluated using by following oral glucose tolerance test (OGTT), liver enzyme and serum lipid profile. All parameters were followed on day o and 30. • analysis was carried out on responders. CD4+CD25+ FOXp3 cells (p<0.01) Total Cholesterol levels (p<0.05) LDL levels (p<0.01) Day 0 Day 30 Insulin secretion at 30 min (p<0.003) OGTT (AUC p<0.002) CD4+CD62+ cells (p<0.03) RESULTS CONCLUSION • Oral administration of HP is safe and exerts an immunomodulatory effect in patients with type 2 diabetes, hyperlipidemia and NASH. • The anti-inflammatory effect and the induction of Tregs are associated with alleviation of insulin resistance, hyperlipidemia, and liver damage in these patients. TNF α levels (p<0.05) IL-6 levels (p<0.05) Administration of Imm122-E improved hepatocellular liver enzymes levels p<0.04. DISCLOSURE * Medical Director of Desert Labs. The study was supported by  Desert Labs Ltd, Israel GLP-1 levels (p<0.03) Improved in BMI (p<0.05)

More Related